foscarnet has been researched along with Skin Diseases, Viral in 9 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
Skin Diseases, Viral: Skin diseases caused by viruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 7.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| "The topical efficacies of foscarnet and acyclovir incorporated into a polyoxypropylene-polyoxyethylene polymer were evaluated and compared to that of 5% acyclovir ointment (Zovirax) by use of a murine model of cutaneous herpes simplex virus type 1 infection." | 7.70 | Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection. ( Bergeron, MG; Désormeaux, A; Gourde, P; Juhász, J; Piret, J, 2000) |
| "The influence of sodium lauryl sulfate (SLS) on the efficacies of topical gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous infection has been evaluated in mice." | 7.70 | Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice. ( Bergeron, MG; Cormier, H; Désormeaux, A; Gourde, P; Juhász, J; Lamontagne, J; Piret, J, 2000) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 7.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "Acyclovir-resistant herpes simplex virus (HSV) infection is common in immunocompromised patients, but the course of such infection is little known." | 3.80 | Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection. ( Agut, H; Boutolleau, D; Burrel, S; Caumes, E; Epelboin, L; Katlama, C; Regnier, S; Seang, S; Valantin, MA; Voujon, D, 2014) |
| "The topical efficacies of foscarnet and acyclovir incorporated into a polyoxypropylene-polyoxyethylene polymer were evaluated and compared to that of 5% acyclovir ointment (Zovirax) by use of a murine model of cutaneous herpes simplex virus type 1 infection." | 3.70 | Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection. ( Bergeron, MG; Désormeaux, A; Gourde, P; Juhász, J; Piret, J, 2000) |
| "The influence of sodium lauryl sulfate (SLS) on the efficacies of topical gel formulations of foscarnet against herpes simplex virus type 1 (HSV-1) cutaneous infection has been evaluated in mice." | 3.70 | Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice. ( Bergeron, MG; Cormier, H; Désormeaux, A; Gourde, P; Juhász, J; Lamontagne, J; Piret, J, 2000) |
| " One patient with AIDS suffered from a perineal lesion due to infection with herpes simplex virus type 2 (HSV-2) and did not respond to acyclovir and was intolerant of foscarnet." | 3.69 | Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC). ( Andrei, G; Balzarini, J; Clumeck, N; De Clercq, E; Gérard, M; Hedderman, A; Sadzot-Delvaux, C; Silverman, A; Snoeck, R; Tricot, G, 1994) |
| "A treatment with foscarnet was administered and clinical improvement was observed as early as the fourth day, with complete reepithelialization 50 days later." | 1.29 | [Chronic herpes resistant to acyclovir in a patient with AIDS]. ( About, I; Bernard, P; Capdeville, J; Massip, P, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seang, S | 1 |
| Boutolleau, D | 1 |
| Burrel, S | 1 |
| Regnier, S | 1 |
| Epelboin, L | 1 |
| Voujon, D | 1 |
| Valantin, MA | 1 |
| Katlama, C | 1 |
| Agut, H | 1 |
| Caumes, E | 1 |
| Brown, TJ | 1 |
| McCrary, M | 1 |
| Tyring, SK | 1 |
| Tan, HH | 1 |
| Goh, CL | 1 |
| About, I | 1 |
| Capdeville, J | 1 |
| Bernard, P | 1 |
| Massip, P | 1 |
| Snoeck, R | 2 |
| Andrei, G | 1 |
| Gérard, M | 1 |
| Silverman, A | 1 |
| Hedderman, A | 1 |
| Balzarini, J | 1 |
| Sadzot-Delvaux, C | 1 |
| Tricot, G | 1 |
| Clumeck, N | 1 |
| De Clercq, E | 1 |
| Lee, MS | 1 |
| Cooney, EL | 1 |
| Stoessel, KM | 1 |
| Gariano, RF | 1 |
| Nikkels, AF | 1 |
| Rentier, B | 1 |
| Pierard, GE | 1 |
| Piret, J | 2 |
| Désormeaux, A | 2 |
| Gourde, P | 2 |
| Juhász, J | 2 |
| Bergeron, MG | 2 |
| Cormier, H | 1 |
| Lamontagne, J | 1 |
3 reviews available for foscarnet and Skin Diseases, Viral
| Article | Year |
|---|---|
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos | 2002 |
Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosine; Drug Ad | 2006 |
Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects.
Topics: Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarnet; Herpesvirus 3, Human; HIV Infect | 1999 |
6 other studies available for foscarnet and Skin Diseases, Viral
| Article | Year |
|---|---|
Long-term follow-up of HIV-infected patients once diagnosed with acyclovir-resistant herpes simplex virus infection.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytosine; Drug | 2014 |
[Chronic herpes resistant to acyclovir in a patient with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Buttocks; Chronic Disease; Drug Resistance; Fo | 1994 |
Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
Topics: Acyclovir; Administration, Topical; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1994 |
Varicella zoster virus retrobulbar optic neuritis preceding retinitis in patients with acquired immune deficiency syndrome.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cerebrospinal Fluid; Fema | 1998 |
Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection.
Topics: Acyclovir; Administration, Topical; Animals; Drug Administration Schedule; Female; Foscarnet; Herpes | 2000 |
Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice.
Topics: Administration, Topical; Animals; Antiviral Agents; Cell Survival; Chemistry, Pharmaceutical; Chloro | 2000 |